NEW YORK, Oct. 5 /PRNewswire/ -- Regenicin™, Inc. (OTC Bulletin Board: WDST) (www.Regenicin.com), a clinical-stage biotechnology company, announced today that Mr. Christopher A. Hadsall, whose primary responsibilities will be to oversee government affairs, has agreed to join the company as Chief Operating Officer. Mr. Hadsall brings 12 years of operational management expertise to Regenicin™ and will be instrumental in working with various military groups to build the company's distribution platform for the future commercialization of PermaDerm™, its proprietary tissue-engineered skin substitute intended to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures.
Commenting on the announcement, Randall McCoy, Chief Executive Officer of Regenicin™ stated, "We are extremely pleased to have Chris join our management team. His strong operational background, along with his proven ability to make a meaningful impact within large care organizations, make him the perfect choice. I look forward to working together with Chris as we build the foundation for Regenicin™'s promising future."
Mr. Hadsall most recently held several key managerial positions with Able Body Labor, a staffing solutions company serving their customers from over 170 branches in 25 states and putting more than 125,000 people to work each year. From 2006 to 2010, Mr. Hadsall was the Regional Manager of Able Body's Westward Ho II subsidiary expansion program where he was responsible for the regional P&L as well as the creation and implementation of a multi-million dollar expansion plan. Under his leadership the region's revenue generation for the company increased five-fold. Prior to heading up that regional expansion, Mr. Hadsa
|SOURCE Regenicin(TM), Inc.|
Copyright©2010 PR Newswire.
All rights reserved